Strategy Group Meeting Agenda

Bethesda Marriott

8:00 a.m.	Registration and Light Refreshments
8:30 a.m.	Introductions Sheila Taube, Ph.D., National Cancer Institute
8:45 a.m.	Embedding and Evaluating Endpoints in Prostate Cancer Trials Prostate 101+: Disease States, Treatment Issues, and the Use of PSA Endpoints Derek Raghaven, M.D., Ph.D., Cleveland Clinic Taussing Cancer Center Endpoint Definitions Lisa McShane, Ph.D., National Cancer Institute Overview of FDA Workshops and Issues Donna Griebel, M.D., U.S. Food and Drug Administration Review of NCI Trials: Opportunities for Endpoint Studies Alison Martin, M.D., National Cancer Institute
11:00 a.m.	Discussion
12:30 p.m.	Lunch
1:15 p.m.	NCI Updates
1:45 p.m.	TAILORx (PACCT-1) Trial
2:15 p.m.	Colon Studies Update
2:45 p.m.	Lung Studies Update
3:15 p.m.	Adjourn